Molecular hybridization is a well-exploited medicinal chemistry strategy that aims to combine
two molecules (or parts of them) in a new, single chemical entity. Recently, it has been …

With 27 million cases worldwide documented in 2006, Alzheimer's disease (AD) constitutes
an overwhelming health, social, economic, and political problem to nations. Unless a new …

The continued drug discovery failures in complex neurodegenerative diseases, including
Alzheimer's disease (AD), has raised questions about the classical paradigm “one‐drug …

Alzheimerβs disease (AD) is a multifactorial neurodegenerative disorder with several target
proteins contributing to its aetiology. Pathological, genetic, biochemical, and modeling …

To date, the pharmacotherapy of Alzheimer's disease (AD) has relied on
acetylcholinesterase (AChE) inhibitors (AChEIs) and, more recently, an N-methyl-D …

The therapeutic arsenal for the treatment of Alzheimer s disease (AD) remains confined to a
group of four inhibitors of AChE and one NMDA receptor antagonist, which are used to …

A design strategy to convert a dual-binding site AChE inhibitor into triple functional
compounds with promising in vitro profile against multifactorial syndromes, such as …

Acetylcholinesterase (AChE; EC 3.1. 1.7) plays a crucial role in the rapid hydrolysis of the
neurotransmitter acetylcholine, in the central and peripheral nervous system and might also …

Inhibitors of acetylcholine breakdown by acetylcholinesterase (AChE) constitute the main
therapeutic modality for Alzheimer's disease. In the search for natural products with …

Neurodegenerative disorders, such as Alzheimer's disease, are often characterised by the
degeneration of the cholinergic system. Thus, the aim of many treatment regimens is to …